The combined NRF1 overexpression and treatment with E2 also led to reprogramming of CD24+ and CD24−CD44− subpopulations with multiple breast cancer stem cell signatures containing ALDH1A1, EpCAM, CXCR4, or CD133. This evidence concerns the gene EPCAM and breast carcinoma.